BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Surging measles cases are 'fire alarm' warning that other diseases could be next - 2Instructions to Explore the Universe of Vehicle Leases
- 3Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- 4A Texas GOP congressman is retiring. Trump just endorsed his identical twin to replace him.
- 5Figure out How to Analyze Medical attendant Compensation Patterns Across Different Specializations
- 5 High Limit Outer Hard Drives For Information Stockpiling
- An Extended period of Voyaging Carefully: the World with Reason
- Common ADHD medication prescribed in childhood may protect against risk of psychosis
- It's your last chance to subscribe to Paramount+ before they raise their prices: Here's how to lock in current pricing
- The Meaning of Breaking the Pen's Nib in Death penalties
- Interoceanic Train derails in southern Mexico, injuring at least 15 and halting traffic on line
- Language Learning Stages: Which One Gets Your Vote?
- Heartfelt Objections to Visit with Your Adored One
- Ergonomic Office Seats for Work spaces
